Brainstorm Cell Therapeutics Inc 2026年季度报告

FORM10-Q (Mark One) or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____________ to _____________Commission File Number 001-36641 (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceeding 12months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ As of May 11, 2026, the number of shares outstanding of the registrant’s Common Stock, $0.00005 par value per share, SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This quarterly report contains numerous statements, descriptions, forecasts and projections, regardingBrainstorm Cell Therapeutics Inc. (together with its consolidated subsidiaries, the “Company,” “Brainstorm,” “we,”“us” or “our”) and its potential future business operations and performance, including financial results for the mostrecent fiscal quarter, statements regarding the market potential for treatment of neurodegenerative disorders such asamyotrophic lateral sclerosis (“ALS”), the sufficiency of our existing capital resources for continuing operations in2026 and beyond, the safety and clinical effectiveness of our NurOwn® technology, our clinical trials of NurOwn®and its related clinical development, and our ability to develop collaborations and partnerships to support ourbusiness plan. In some cases you can identify such “forward-looking statements” by the use of words like “may,”“will,”“should,”“could,”“expects,”“hopes,”“anticipates,”“believes,”“intends,”“plans,”“projects,”“targets,” “goals,” “estimates,” “predicts,” “likely,” “potential,” or “continue” or the negative of any of these termsor similar words. These statements, descriptions, forecasts and projections constitute “forward-looking statements,”and as such involve known and unknown risks, uncertainties, and other factors that may cause our actual results,levels of activity, performance and achievements to be materially different from any results, levels of activity,performance and achievements expressed or implied by any such “forward-looking statements.” These risks anduncertainties include, but are not limited to the potential consequences of our delisting from The Nasdaq Stock Market(the “Nasdaq”) and our common stock trading on the OTCQB Venture Market on the liquidity and price of ourcommon stock; the outcomes of the putative securities class action and derivative lawsuits filed by five of ourshareholders, the potential for more derivative lawsuits to be brought, our need to raise additional capital, our abilityto continue as a going concern, regulatory approval of our NurOwn® treatment candidate, the success of our productdevelopment programs and research, regulatory and personnel issues, development of a global market for ourservices, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generatesignificant revenue, the ability of our NurOwn® treatment candidate to achieve broader acceptance as a treatmentoption for ALS, progressive multiple sclerosis (“PMS”), Alzheimer’s disease(“AD”) or other neurodegenerativediseases, our ability to manufacture and commercialize our NurOwn® treatment candidate, obtaining patents thatprovide meaningful protection, competition and market developments, our ability to protect our intellectual propertyfrom infringement by third parties, heath reform legislation, demand for our services, currency exchange rates andproduct liability claims and litigation, adverse developments affecting the financial services industry, politicalinstability, unrest and wars, such as the conflicts involving Ukraine and Russia and Israel and its